Overweight and obesity in adults: Recommendations and treatment algorhytms;Recomendaciones y algoritmo de tratamiento del sobrepeso y la obesidad en personas adultas

Medicina Clinica

Volumn 122, Issue 3, 2004, Pages 104-110

  Arrizabalaga, Juan José ^a   Masmiquel, Lluís ^a   Vidal, Josep ^a   Calañas Continente, Alfonso ^a   Díaz Fernández, María José ^a   García Luna, Pedro Pablo ^a   Monereo, Susana ^a   Moreiro, José ^a   Moreno, Basilio ^a   Ricart, Wifredo ^a   Cordido, Fernando ^a,b  

^a Grupo de Trabajo Sobre Obesidad   (Spain)

^b Soc Espanola de Endocrinol y Nutr   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADULT; ALGORITHM; CARDIOVASCULAR RISK; CONFERENCE PAPER; HUMAN; LIFESTYLE; LOW CALORY DIET; OBESITY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; TREATMENT INDICATION;

EID: 10744229928     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13056816     Document Type: Conference Paper

References (66)

1. SIGN. Obesity in Scotland: integrating prevention with weight management. A National Clinical Guideline. Edinburgh: Scottish Intercollegiate Guidelines Network, 1996; p. 1-71. Disponible en: http://www.sign.ac.uk
2. National Institutes of Health. National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. Bethesda: National Heart, Lung, and Blood Institute, 1998: p. i-228. Disponible en: http://www.nhlbi.nih.gov/nhlbi/nhlbi.htm
3. The National Heart, Lung, and Blood Institute Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998;158:1855-67.
4. Grupo de Trabajo sobre Obesidad de la Sociedad Española de Endocrinología y Nutrición. Guía de Práctica Clínica para el manejo del sobrepeso y la obesidad en personas adultas. Endocrinología y Nutrición 2003 (en prensa).
5. Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developers' handbook. Edinburgh: SIGN, 2001. Disponible en: www.sign.ac.uk/guidelines/fulltext/50/index.html
6. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva: World Health Organization, 1998; p. 1-276.
7. Sociedad Española para el Estudio de la Obesidad (SEEDO). Consenso SEEDO 2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Med Clin (Barc) 2000;115:587-97.
8. Jansen I, Katzmarzyk PT, Ross R. Body mass index, waist circumference, and health Risk. Arch Intern Med 2002;162:2074-9.
9. National Institutes of Health, National Hearth, Lung, and Blood Institute, North American Association for the Study of Obesity. The Practical Guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethesda: National Institutes of Health, National Hearth, Lung, and Blood Institute, North American Association for the Study of Obesity, NIH Publication n.° 00-4048, 2000; p. 1-77. Disponible en: http://www.nhlbi.nih.gov/guidelines/obesity/practgde.htm
10. Noël PH, Pugh JA. Clinical review: management of overweight and obese adults. BMJ 2002;325:757-61.
11. Asp NG, Björntorp P, Britton M, Carlsson P, Kjellström T, Marcus C, et al. Behandling av fetma hos vuxna. En: Asp NG, Björntorp P, Britton M, Carlsson P, Kjellström T, Marcus C, et al, editors. Fetma -problem och åtgärder. Stockholm: Statens beredning för medicinsk utvärdering (SBU), SBU Report No 160, 2002:143-296 (para un resumen y conclusiones en lengua inglesa, véase la referencia siguiente).
12. o 160, 2002. Disponible en: http://www.sbu.se/
13. Glenny AM, O'Meara S, Melville A, Sheldon TA, Wilson C. The treatment and prevention of obesity: a systematic review of the literature. Int J Obes Relat Metab Disord 1997;21:715-37.
14. NHS Centre for Reviews and Dissemination. The prevention and treatment of obesity. Effective Health Care 1997;3:1-12.
15. Douketis JD, Feightner JW, Attia J, Feldman WF, with the Canadian Task Force on Preventive Health Care. Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity. CMAJ 1999;160:513-25.
16. Wadden TA. Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials. Ann Intern Med 1993;119(7: part 2):688-93.
17. nd ed. Philadelphia: Lippincott-Raven, 1996; p. 197-217.
18. Arterburn D, Noël PH. Clinical review: obesity. BMJ 2001;321:1406-9.
19. O'Meara S, Riemsma R, Shirran L, Mather L, Ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001;5:1-71.
20. O'Meara S, Riemsma R, Shirran L, Mather L, Ter Riet G. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment. Health Technol Assess 2002;6:1-82.
21. Foxcroft D, Ludders J. Orlistat for the treatment of obesity. Southampton: Wessex Institute for Health Research and Development, Report No 101, 1999; p. 1-49.
22. Orlistat: no hurry. Can Fam Physician 1999;45:2331-51.
23. Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, Von Bergmann K, et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord 1995;19:221-6.
24. Drent ML, Van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes Relat Metab Disord 1993;17:241-4.
25. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 1998;54:125-32.
26. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. European public assessment report (EPAR): Xenical. London: EMEA, 1998; p. 1-38.
27. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160-7.
28. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 tears treatment with orlistat for obesity. Obes Res 2000;8:49-61.
29. Lindgärde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Int Med 2000;248:245-54.
30. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998;21:1288-94.
31. Sjöstrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-73.
32. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281:235-42.
33. Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr 1999;69:1108-16.
34. Finer N, James WTP, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomized double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000;24:306-13.
35. National Institute for Clinical Excellence. Guidance on the use of orlistat for the treatment of obesity in adults. London: National Institute for Clinical Excellence, Technology Appraisal Guidance No 22, 2001; p. 1-12.
36. Luque CA, Rey JA. Sibutramine: a serotonin-noerpinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 1999;33:968-78.
37. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weiht control: a dose-ranging, eficacy study. Clin Pharmacol Ther 1991;50:330-7.
38. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord 1998;22:32-8.
39. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189-98.
40. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-84.
41. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999;23:1016-24.
42. Seagle HM, Bessesen DH, Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res 1998;6:115-21.
43. Walsh KM, Leen E, Lean ME. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord 1999;23:1009-15.
44. Fanghanel G, Cortinas L, Sánchez Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord 2000;24:144-50.
45. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000;2:105-12.
46. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebowitz HE, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000;2:175-87.
47. Cuellar GEM, Ruiz AM, Monsalve MCR, Berber A. Six-month treatment of obesity with sibutramine 15 mg: a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 2000;8:71-82.
48. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, et al. Efficacy and safety of sibutramine in obese white and african american patients with hypertension: a 1-year, double-bind, placebo-controlled multicenter trial. Arch Intern Med 2000;160:2185-91.
49. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000;356:2119-25.
50. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;50:505-12.
51. Dujovne CA, Zavoral JH, Rowe E, Mendel CM. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipemia. Am Heart J 2001;142:489-97.
52. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001;286:1331-9.
53. Gokcel A, Karakose H, Ertorer EM, Tanci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with tipe 2 diabetes and poor blood glucose control. Diabetes Care 2001;24:1957-60.
54. Astrup A, Chong E. Weight loss produced by sibutramine: a meta-analysis [abstract]. Int J Obes Relat Metab Disord 2001;25(Suppl 2):104.
55. Jones SP, Smith IG, Kelly F, Gray JA. Long-term weight loss with sibutramine [abstract]. Int J Obes Relat Metab Disord 1995(Suppl 2):41.
56. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Comparison of sibutramine and dexfenfluramine i the treatment of obesity. Obes Res 1998;6:285-91.
57. National Institute for Clinical Excellence. Guidance on the use of sibutramine for the treatment of obesity in adults. London: National Institute for Clinical Excellence, Technology Appraisal Guidance No. 31,2001; p. 1-12.
58. Asp NG, Björntorp P, Britton M, Carlsson P, Kjellström T, Marcus C, et al. Alternativmedicinsk behandling. En: Asp NG, Björntorp P, Britton M, Carlsson P, Kjellström T, Marcus C, et al, editors. Fetma - problem och åtgärder. Stockholm: Statens beredning för medicinsk utvärdering (SBU), SBU Report No 160, 2002; p. 297-322.
59. Allison DB, Fontaine KR, Heshka S, Mentore JL, Heymsfield SB. Alternative treatments for weight loss: a critical review. Crit Rev Food Sci Nutr 2001;41:1-28.
60. NIH Consensus Development Panel. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Ann Intern Med 1991;115:956-61.
61. Conseil d'Evaluation des Technologies de la Santé du Québec. Le traitement chirurgical de l'obesité morbide. Montréal: CETS, 1998:1-102.
62. Agence Nationale d'Accreditation, et d'Evaluation en Santé. Chirurgie de l'obesité morbide de l'adulte. Paris: ANAES, 2000; p. 1-111.
63. Schneider WL. Laparoscopic adjustable gastric banding for clinically severe (morbid) obesity. Edmonton: Alberta Heritage Foundation for Medical Research, HTA 7: Series B, Health Technology Brief, 2000; p. i-30.
64. nd ed. Adelaide, South Australia: ASERNIP-S, 2002; p. 1-147.
65. Clegg AJ, Colquitt J, Sidhu MK, Royle P, Loveman E, Walker A. The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation. Health Technol Assess 2002;6:1-154.
66. National Institute for Clinical Excellence. Guidance on the use of surgery to aid weight reduction for people with morbid obesity. London: National Institute for Clinical Excellence, Technology Appraisal Guidance No. 46, 2002; p. 1-24.